Market Place
Sourcing Support
Poseida Therapeutics Reports Q3 2024 Financials & Updates
07 Nov 2024 //
PR NEWSWIRE
Poseida Present Data Supporting Gene Edit For Hereditary Angioedema
24 Oct 2024 //
PR NEWSWIRE
Poseida Reports Positive Phase 1 Results For P-BCMA-ALLO1
27 Sep 2024 //
PR NEWSWIRE
Poseida Therapeutics Presents Ph 1 Data on CAR-T P-BCMA-ALLO1 at Myeloma Meeting
05 Sep 2024 //
PR NEWSWIRE
Poseida Provides Updates, Q1 2024 Financial Results
14 May 2024 //
PR NEWSWIRE
Astellas adds to ‘off-the-shelf’ cell therapy capabilities with Poseida deal
02 May 2024 //
PR NEWSWIRE
Poseida Presents New Phase 1 Data at AACR 2024
08 Apr 2024 //
PR NEWSWIRE
Poseida Therapeutics to Present at H.C. Wainwright 2nd Cell Therapy Conference
19 Mar 2024 //
PR NEWSWIRE
Poseida makes case for safety of Roche-partnered nonviral CAR-T
10 Dec 2023 //
FIERCE BIOTECH
Poseida promotes cell therapy president to CEO; Neumora appoints R&D chief
13 Oct 2023 //
ENDPTS
Poseida Announces FDA Clearance of Investigational NDA for P-CD19CD20-ALLO1
05 Jul 2023 //
PR NEWSWIRE
Poseida Presents Preclinical Data Across its Gene Therapy Programs
18 May 2023 //
PR NEWSWIRE
Poseida Therapeutics Provides Updates and Financial Results for the 1Q of 2023
09 May 2023 //
PR NEWSWIRE
Poseida Therapeutics Names Kristin Yarema President, Cell Therapy
11 Apr 2023 //
CONTRACT PHARMA
Poseida Provides Financial Results for the Fourth Quarter and Full Year 2022
09 Mar 2023 //
PR NEWSWIRE
Poseida Appoints Five New Members to Its Gene Therapy Scientific Advisory Board
01 Mar 2023 //
PR NEWSWIRE
Poseida to Present at H.C. Wainwright Cell Therapy Virtual Conference
14 Feb 2023 //
PR NEWSWIRE
Poseida Therapeutics to Host Third Annual Virtual R&D Day on February 22, 2023
08 Feb 2023 //
PR NEWSWIRE
Takeda, Poseida see promising data for hemophilia A gene therapy
14 Dec 2022 //
FIERCEBIOTECH
Poseida Therapeutics Provides Updates and Financial Results for the 2Q of 2022
11 Aug 2022 //
PRNEWSWIRE
Poseida Therapeutics Announces Closing of Public Offering of Common Stock
08 Aug 2022 //
PRESS RELEASE
Poseida Therapeutics Announces Proposed Public Offering of Common Stock
03 Aug 2022 //
PRESS RELEASE
Roche wagers $190M on off-the-shelf CAR-Ts and ex-Biogen asset
03 Aug 2022 //
FIERCEBIOTECH
Poseida Tx Announces Strategic Global Collaboration with Roche
03 Aug 2022 //
PRNEWSWIRE
Poseida Therapeutics Announces Virtual 2022 Annual Meeting of Stockholders
02 Jun 2022 //
PRNEWSWIRE
Poseida Therapeutics Appoints Charles M. Baum to Board of Directors
18 May 2022 //
PRNEWSWIRE
Poseida Therapeutics to Present at ASGCT Annual Meeting
02 May 2022 //
PRNEWSWIRE
Poseida Therapeutics to Present at BofA Securities 2022 Healthcare Conference
28 Apr 2022 //
PRNEWSWIRE
Poseida Tx Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
01 Mar 2022 //
PRNEWSWIRE
Poseida taps former Novartis VP as president of gene therapy
23 Feb 2022 //
FIERCEBIOTECH
Poseida Therapeutics Appoints Brent Warner as President, Gene Therapy
22 Feb 2022 //
PRNEWSWIRE
Poseida Tx to Present Interim Results from Phase 1 Trial of P-PSMA-101
17 Feb 2022 //
PRNEWSWIRE
Poseida Therapeutics to Host Virtual R&D Day on February 23, 2022
09 Feb 2022 //
PRNEWSWIRE
Eric Ostertag reaching the end of the line as Poseida chief, and more
14 Jan 2022 //
ENDPTS
Poseida Therapeutics Announces Eric Ostertag to Serve as Executive Chairman
10 Jan 2022 //
PRNEWSWIRE
Poseida Goes All-In on Allogeneic CAR-T; Ligand Explores Spin-Off
11 Nov 2021 //
BIOSPACE
Spooky SPAC season and a $180M Entrada onto Wall Street
30 Oct 2021 //
MARKETWATCH
Poseida, Takeda ink $3.6B pact for 8 non-viral gene therapies
13 Oct 2021 //
FIERCEBIOTECH
Poseida Therapeutics to Present at Upcoming Virtual Investor Conferences
07 Sep 2021 //
PRNEWSWIRE
Poseida hopes for reprieve with early solid tumor CAR-T data
31 Aug 2021 //
FIERCEBIOTECH
Poseida offers proof of efficacy for a next-gen solid tumor CAR-T
31 Aug 2021 //
ENDPTS
Poseida Presents Results from Phase 1 Trial of P-PSMA-101 at CAR-TCR Summit
31 Aug 2021 //
PRNEWSWIRE
Poseida Therapeutics Announces FDA Clearance of NDA for P-BCMA-ALLO1
30 Aug 2021 //
PRNEWSWIRE
Poseida Therapeutics Reports Program Updates and Financial Results
12 Aug 2021 //
PRNEWSWIRE
Poseida Therapeutics Appoints Cynthia Collins to Board of Directors
26 Jul 2021 //
PRNEWSWIRE
Poseida partners with Cellares on cell therapy factory in a box
14 Jul 2021 //
FIERCEPHARMA
Cellares, Poseida Therapeutics partner to accelerate cell therapy
14 Jul 2021 //
PHARMABIZ
Cellares, Poseida Therapeutics partner to accelerate cell therapy
14 Jul 2021 //
PHARMABIZ
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T
11 May 2021 //
PRNEWSWIRE
Poseida Therapeutics Presents Encouraging Preclinical Data Across its CAR-T
11 May 2021 //
PRNEWSWIRE
Poseida to Present at American Society of Gene and Cell Therapy 2021
27 Apr 2021 //
PRNEWSWIRE
Poseida to Present at American Society of Gene and Cell Therapy 2021
27 Apr 2021 //
PRNEWSWIRE
AbbVie partner Teneobio expands tech license with CAR-T player Poseida
23 Nov 2020 //
ENDPTS
Poseida Therapeutics Announces Clinical Hold Lifted on Phase I Autologous
02 Nov 2020 //
PIPELINEREVIEW
Poseida Therapeutics Added to Membership of US Small-Cap Russell 2000® Index
18 Sep 2020 //
BIOSPACE
Poseida shares plunge after death in solid tumor CAR-T trial, clinical hold
18 Aug 2020 //
FIERCEBIOTECH
Poseida Therapeutics` study of P-PSMA-101 placed on hold after patient death
17 Aug 2020 //
THEFLY
Newly arrived on Nasdaq, Poseida quietly signals a clinical hold triggered
17 Aug 2020 //
ENDPTS
Poseida tees $150M IPO; Gilead sends HBV program back to Precision; New HIV data
06 Jul 2020 //
ENDPTS
Malin-backed Poseida Therapeutics files for IPO on Nasdaq exchange
21 Jun 2020 //
IRISHTIMES
